Reports of Guillain-Barré syndrome (GBS ... During prelicensure clinical trials, GBS was identified as a potential safety concern, and the rates of GBS after RSV vaccination are in general ...

Guillain-Barré syndrome (GBS ... The authors included 174 patients who participated in one of two previous clinical trials, all of whom had been treated with 2 g/kg of IVIg.

BACKGROUND: The subacute demyelinating polyneuropathy known as Guillain-Barré syndrome improves more rapidly with plasma exchange than with supportive care alone. We conducted a multicenter trial ...

Annexon’s lead candidate, ANX005, shows promise for treating Guillain-Barré Syndrome, achieving significant improvement in muscle strength and disability in phase 3 trials. Despite setbacks ...